Albumin-Bound Paclitaxel /nab-Paclitaxel is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1), Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) and The First Affiliated Hospital with Nanjing Medical University (1). Registered phase: Phase 2. Conditions studied include Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma (HNSCC).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07601737 | Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer |
Phase 2 | Recruiting |
| NCT07668453 | An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies (ClinicalTrials.gov ↗) Biliary Tract Neoplasms |
Phase 2 | Recruiting |
| NCT06511726 | Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer Cervical Cancer |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Cervical Cancer | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Head and Neck Squamous Cell Carcinoma (HNSCC) | 1 |
| Head & Neck Cancer | 1 |
| Neoadjuvant Therapy | 1 |
| Biliary Tract Neoplasms | 1 |
| Lead sponsor | Trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Register | Albumin-Bound Paclitaxel /nab-Paclitaxel trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Albumin-Bound Paclitaxel /nab-Paclitaxel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Albumin-Bound Paclitaxel /nab-Paclitaxel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.